Literature DB >> 32730904

Association of sputum microbiome with clinical outcome of initial antibiotic treatment in hospitalized patients with acute exacerbations of COPD.

Haiyue Liu1, Daowen Zheng1, Yanxia Lin2, Zuheng Liu3, Zhenyu Liang4, Jin Su2, Rongchang Chen4, Hongwei Zhou5, Zhang Wang6.   

Abstract

Identification of risk factors for antibiotic treatment failure is urgently needed in acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Here we investigated the relationship between sputum microbiome and clinical outcome of choice of initial antibiotics during hospitalization of AECOPD patients. Sputum samples of 41 AECOPD patients and 26 healthy controls were collected from Guangzhou Medical University, China. Samples were processed for 16S rRNA gene-based microbiome profiling. Thirty patients recovered with initial antibiotic treatment (antibiotic success or AS), while 11 patients showed poor outcome (antibiotic failure or AF). Substantial differences in microbiome were observed in AF versus AS patients and healthy controls. There was significantly decreased alpha diversity and increased relative abundances of Pseudomonas, Achromobacter, Stenotrophomonas and Ralstonia in AF patients. Conversely, Prevotella, Peptostreptococcus, Leptotrichia and Selenomonas were depleted. The prevalence of Selenomonas was markedly reduced in AF versus AS patients (9.1 % versus 60.0 %, P = 0.004). The AF patients with similar microbiome profiles in general responded well to the same new antibiotics in the adjusted therapy, indicating sputum microbiome may help guide the adjustment of antibiotics. Random forest analysis identified five microbiome operational taxonomic units together with C-reactive protein, procalcitonin and blood neutrophil count showing best predictability for antibiotic treatment outcome (area under curve 0.885). Functional inference revealed an enrichment of microbial genes in xenobiotic metabolism and antimicrobial resistance in AF patients, whereas genes in DNA repair and amino acid metabolism were depleted. Sputum microbiome may determine the clinical outcome of initial antibiotic treatment and be considered in the risk management of antibiotics in AECOPD.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AECOPD; Cefoperazone-tazobactam (PubChem CID: 23663974 & PubChem CID: 123630); Etimicin (PubChem CID: 9912913); Initial antibiotics; Levofloxacin (PubChem CID: 149096); Linezolid (PubChem CID: 441401); Lung microbiome; Meropenem (PubChem CID: 441130); Moxalactam (PubChem CID: 47499); Multidrug resistant bacteria; Piperacillin-sulbactam (PubChem CID: 119561); Teicoplanin (PubChem CID: 16129710, PubChem CID: 16198036, PubChem CID: 17748671, PubChem CID: 17748672, PubChem CID: 17748673 & PubChem CID: 16152170); Treatment outcome

Year:  2020        PMID: 32730904     DOI: 10.1016/j.phrs.2020.105095

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  4 in total

1.  Informatic analysis of the pulmonary microecology in non-cystic fibrosis bronchiectasis at three different stages.

Authors:  Yuchao Wang; Ying Chen; Chao Wu; Xiaohong Yang
Journal:  Open Life Sci       Date:  2022-02-28       Impact factor: 1.311

2.  Investigation on the Pathological Mechanism of Frequent Exacerbators With Chronic Obstructive Pulmonary Disease Based on the Characteristics of Respiratory Flora.

Authors:  Li Ke; Luo Chen; Yuan Yaling; Gao Can; Lin Jun; Zhang Chuan
Journal:  Front Med (Lausanne)       Date:  2022-01-20

3.  A Risk Prediction Model for Prolonged Length of Stay in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Retrospective Study of 225 Patients in a Single Center in Kunming, China.

Authors:  Lifen Yang; Meihua Li; Jingkui Shu; Yanxia Yang; Qian Huang
Journal:  Med Sci Monit       Date:  2022-02-09

Review 4.  Unmet needs in the management of exacerbations of chronic obstructive pulmonary disease.

Authors:  Kiki Waeijen-Smit; Sarah Houben-Wilke; Antonio DiGiandomenico; Ulf Gehrmann; Frits M E Franssen
Journal:  Intern Emerg Med       Date:  2021-02-22       Impact factor: 3.397

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.